Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 YearsThe Motley Fool • 06/30/26
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drugReuters • 06/30/26
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland ChinaPRNewsWire • 06/30/26
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reportsReuters • 06/29/26
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilitiesCNBC • 06/29/26
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yetCNBC • 06/28/26
Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally RotatesInvestors Business Daily • 06/27/26
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverageCNBC • 06/26/26
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyPRNewsWire • 06/26/26
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees.The Motley Fool • 06/25/26
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementPRNewsWire • 06/25/26
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPRNewsWire • 06/24/26